Abstract:Abstract Background Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer’s disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quantitative metabolomics was applied to plasma and cerebrospinal fluid (CSF) from clinically well-characterized AD patients and cognitively healthy control subjects. The observed metabolic alterations were associated with core pathological processes of AD to investigate their relation with amyloid pathology and tau-related neurodegeneration. Methods In a case-control study of clinical and biomarker-confirmed AD patients ( n = 40) and cognitively healthy controls without cerebral AD pathology ( n = 34) with paired plasma and CSF samples, we performed metabolic profiling, i.e., untargeted metabolomics and targeted quantification. Targeted quantification focused on identified deregulated pathways highlighted in the untargeted assay, i.e. the TCA cycle, and its anaplerotic pathways, as well as the neuroactive tryptophan and kynurenine pathway. Results Concentrations of several TCA cycle and beta-oxidation intermediates were higher in plasma of AD patients, whilst amino acid concentrations were significantly lower. Similar alterations in these energy metabolism intermediates were observed in CSF, together with higher concentrations of creatinine, which were strongly correlated with blood-brain barrier permeability. Alterations of several amino acids were associated with CSF Amyloidβ1–42. The tryptophan catabolites, kynurenic acid and quinolinic acid, showed significantly higher concentrations in CSF of AD patients, which, together with other tryptophan pathway intermediates, were correlated with either CSF Amyloidβ1–42, or tau and phosphorylated Tau-181. Conclusions This study revealed AD-associated systemic dysregulation of nutrient sensing and oxidation and CNS-specific alterations in the neuroactive tryptophan pathway and (phospho)creatine degradation. The specific association of amino acids and tryptophan catabolites with AD CSF biomarkers suggests a close relationship with core AD pathology. Our findings warrant validation in independent, larger cohort studies as well as further investigation of factors such as gender and APOE genotype, as well as of other groups, such as preclinical AD, to identify metabolic alterations as potential intervention targets.

Glutamate and GABA-Metabolizing Enzymes in Post-mortem Cerebellum in Alzheimer’s Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase

Comprehensive Analysis of Metabolites in Postmortem Brains of Patients with Alzheimer's Disease

The glutamatergic system in Alzheimer's disease: a systematic review with meta-analysis

A postmortem study of amino acid neurotransmitters in Alzheimer's disease

Alzheimer’s disease: amino acid levels and brain metabolic status

Brain Glutamate Levels Are Decreased in Alzheimer’s Disease

GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer's disease

Single-nucleus transcriptional profiling uncovers the reprogrammed metabolism of astrocytes in Alzheimer's disease.

Reduced uptake of [11C]‐ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer’s dementia

Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy

d-glutamate and Gut Microbiota in Alzheimer’s Disease

Cerebral glucose metabolism in Alzheimer's disease

Associations of Plasma Glutamatergic Metabolites with Alpha Desynchronization during Cognitive Interference and Working Memory Tasks in Asymptomatic Alzheimer's Disease

Glycolytic and Proteolytic Metabolism in Erythrocytes from Elderly and Demented Patients

The study of the abnormality of metabolism rate of glucose of cerebral white matter in Alzheimer's disease

Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients

Altered microglia and neurovasculature in the Alzheimer's disease cerebellum

Antemortem laboratory diagnosis of Alzheimer's disease

Systemic and central nervous system metabolic alterations in Alzheimer’s disease

Multi‐omics approach reveals disturbances in brain phosphatidylcholine metabolism in Alzheimer’s Disease

Identifying Differences in Bile Acid Pathways for Cholesterol Clearance in Alzheimer’s Disease Using Metabolic Networks of Human Brain Regions